Antiretroviral therapy in primary HIV-1 infection: Influences on immune activation and gut mucosal barrier dysfunction

AIDS Reviews

Volumn 17, Issue 3, 2015, Pages 135-146

  Cao, Wei ^a,b,c   Mehraj, Vikram ^a,b   Vyboh, Kishanda ^a,b   Li, Taisheng ^c   Routy, Jean Pierre ^a,b  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^c PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

Antiretroviral therapy; Gut mucosal barrier dysfunction; HIV 1 reservoir; Immune activation; Primary HIV 1 infection

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DISEASE COURSE; ENTEROPATHY; EVIDENCE BASED PRACTICE; GUT MUCOSAL BARRIER DYSFUNCTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RESPONSE; IMMUNOREACTIVITY; INTESTINE FLORA; INTESTINE LYMPHATIC TISSUE; OUTCOME ASSESSMENT; TH17 CELL; VIRUS REPLICATION; BACTERIAL TRANSLOCATION; COMBINATION DRUG THERAPY; DRUG EFFECTS; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; INTESTINE MUCOSA; LYMPHOCYTE ACTIVATION; MUCOSAL IMMUNITY; PATHOPHYSIOLOGY; TREATMENT OUTCOME; VIROLOGY;

ANTI-HIV AGENTS; BACTERIAL TRANSLOCATION; CD4-POSITIVE T-LYMPHOCYTES; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV-1; HUMANS; IMMUNITY, MUCOSAL; INTESTINAL MUCOSA; LYMPHOCYTE ACTIVATION; TH17 CELLS; TREATMENT OUTCOME;

EID: 84945949261     PISSN: 11396121     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (75)

1. Cooper DA, Gold J, Maclean P, et al. Acute AIDS retrovirus infection. Definition of a clinical illness associated with seroconversion. Lancet. 1985;1:537-40.
2. Fiebig EW, Wright DJ, Rawal BD, et al. Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS. 2003;17:1871-9.
3. Brenner BG, Roger M, Routy JP, et al. High rates of forward transmission events after acute/early HIV-1 infection. J Infect Dis. 2007;195:951-9.
4. Hamlyn E, Jones V, Porter K, Fidler S. Antiretroviral treatment of primary HIV infection to reduce onward transmission. Curr Opin HIV AIDS. 2010;5:283-90.
5. Borrow P, Lewicki H, Hahn BH, Shaw GM, Oldstone MB. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol. 1994;68:6103-10.
6. Wilson JD, Ogg GS, Allen RL, et al. Direct visualization of HIV-1-specific cytotoxic T lymphocytes during primary infection. AIDS. 2000;14:225-33.
7. Goonetilleke N, Liu MK, Salazar-Gonzalez JF, et al. The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. J Exp Med. 2009;206:1253-72.
8. Turnbull EL, Wong M, Wang S, et al. Kinetics of expansion of epitopespecific T cell responses during primary HIV-1 infection. J Immunol. 2009;182:7131-45.
9. Streeck H, Lu R, Beckwith N, et al. Emergence of individual HIV-specific CD8 T cell responses during primary HIV-1 infection can determine long-term disease outcome. J Virol. 2014;88:12793-801.
10. Trautmann L, Mbitikon-Kobo FM, Goulet JP, et al. Profound metabolic, functional, and cytolytic differences characterize HIV-specific CD8 T cells in primary and chronic HIV infection. Blood. 2012;120:3466-77.
11. Claiborne DT, Prince JL, Scully E, Macharia G, Micci L, Lawson B, et al. Replicative fitness of transmitted HIV-1 drives acute immune activation, proviral load in memory CD4+ T cells, and disease progression. Proc Natl Acad Sci USA. 2015;112:E1480-9.
12. Prince JL, Claiborne DT, Carlson JM, et al. Role of transmitted Gag CTL polymorphisms in defining replicative capacity and early HIV-1 pathogenesis. PLoS Pathog. 2012;8:e1003041.
13. Radebe M, Gounder K, Mokgoro M, et al. Broad and persistent Gagspecific CD8+ T-cell responses are associated with viral control but rarely drive viral escape during primary HIV-1 infection. AIDS. 2015;29:23-33.
14. Blackburn SD, Shin H, Haining WN, et al. Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol. 2009;10:29-37.
15. Gaiha GD, McKim KJ, Woods M, et al. Dysfunctional HIV-specific CD8+ T cell proliferation is associated with increased caspase-8 activity and mediated by necroptosis. Immunity. 2014;41:1001-12.
16. Doitsh G, Galloway NL, Geng X, et al. Cell death by pyroptosis drives CD4 T-cell depletion in HIV-1 infection. Nature. 2014;505:509-14.
17. Soghoian DZ, Jessen H, Flanders M, et al. HIV-specific cytolytic CD4 T cell responses during acute HIV infection predict disease outcome. Sci Transl Med. 2012;4:123ra25.
18. Frater J, Ewings F, Hurst J, et al. HIV-1-specific CD4(+) responses in primary HIV-1 infection predict disease progression. AIDS. 2014;28:699-708.
19. Chun TW, Engel D, Berrey MM, Shea T, Corey L, Fauci AS. Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection. Proc Natl Acad Sci USA. 1998;95:8869-73.
20. Whitney JB, Hill AL, Sanisetty S, et al. Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys. Nature. 2014;512:74-7.
21. Ananworanich J, Schuetz A, Vandergeeten C, et al. Impact of multitargeted antiretroviral treatment on gut T cell depletion and HIV reservoir seeding during acute HIV infection. PLoS One. 2012;7:e33948.
22. Ananworanich J, Vandergeeten C, Chomchey N, et al. Early ART Intervention Restricts the Seeding of the HIV Reservoir in Long-lived Central Memory CD4 T Cells. CROI. 2013 Atlanta, GA. [Abstract 47].
23. Chomont N, El-Far M, Ancuta P, et al. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med. 2009;15:893-900.
24. Kotler DP, Gaetz HP, Lange M, Klein EB, Holt PR. Enteropathy associated with the acquired immunodeficiency syndrome. Ann Intern Med. 1984;101:421-8.
25. Brenchley JM, Schacker TW, Ruff LE, et al. CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med. 2004;200:749-59.
26. Guadalupe M, Reay E, Sankaran S, et al. Severe CD4+ T-cell depletion in gut lymphoid tissue during primary human immunodeficiency virus type 1 infection and substantial delay in restoration following highly active antiretroviral therapy. J Virol. 2003;77:11708-17.
27. Chun TW, Nickle DC, Justement JS, et al. Persistence of HIV in gutassociated lymphoid tissue despite long-term antiretroviral therapy. J Infect Dis. 2008;197:714-20.
28. Allers K, Puyskens A, Epple HJ, et al. The effect of timing of antiretroviral therapy on CD4 T-cell reconstitution in the intestine of HIV-infected patients. Mucosal Immunol. 2015. [Epub ahead of print].
29. Brenchley JM, Price DA, Schacker TW, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med. 2006;12:1365-71.
30. Epple HJ, Allers K, Troger H, et al. Acute HIV infection induces mucosal infiltration with CD4+ and CD8+ T cells, epithelial apoptosis, and a mucosal barrier defect. Gastroenterology. 2010;139:1289-300.
31. Liang SC, Tan XY, Luxenberg DP, et al. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J Exp Med. 2006;203:2271-9.
32. Brenchley JM, Paiardini M, Knox KS, et al. Differential Th17 CD4 T-cell depletion in pathogenic and nonpathogenic lentiviral infections. Blood. 2008;112:2826-35.
33. Schuetz A, Deleage C, Sereti I, et al. Initiation of ART during early acute HIV infection preserves mucosal Th17 function and reverses HIV-related immune activation. PLoS Pathog. 2014;10:e1004543.
34. Shaw JM, Hunt PW, Critchfield JW, et al. Increased frequency of regulatory T cells accompanies increased immune activation in rectal mucosae of HIV-positive noncontrollers. J Virol. 2011;85:11422-34.
35. Epple HJ, Loddenkemper C, Kunkel D, et al. Mucosal but not peripheral FOXP3+ regulatory T cells are highly increased in untreated HIV infection and normalize after suppressive HAART. Blood. 2006;108:3072-8.
36. Jenabian MA, Patel M, Kema I, et al. Distinct tryptophan catabolism and Th17/Treg balance in HIV progressors and elite controllers. PLoS One. 2013;8:e78146.
37. Jenabian MA, El-Far M, Vyboh Ket al. Immunosuppressive tryptophan catabolism and gut mucosal dysfunction following early HIV infection. J Infect Dis. 2015;212:355-66.
38. Hunt PW, Sinclair E, Rodriguez B, et al. Gut epithelial barrier dysfunction and innate immune activation predict mortality in treated HIV infection. J Infect Dis. 2014;210:1228-38.
39. Bell SK, Little SJ, Rosenberg ES. Clinical management of acute HIV infection: best practice remains unknown. J Infect Dis. 2010;202(Suppl 2):S278-88.
40. Hogan CM, Degruttola V, Sun X, et al. The setpoint study (ACTG A5217): effect of immediate versus deferred antiretroviral therapy on virologic set point in recently HIV-1-infected individuals. J Infect Dis. 2012;205:87-96.
41. Fidler S, Porter K, Ewings F, et al. Short-course antiretroviral therapy in primary HIV infection. N Engl J Med. 2013;368:207-17.
42. Grijsen ML, Steingrover R, Wit FW, et al. No treatment versus 24 or 60 weeks of antiretroviral treatment during primary HIV infection: the randomized Primo-SHM trial. PLoS Med. 2012;9:e1001196.
43. Grijsen ML, Wit FW, Jurriaans S, et al. Temporary treatment during primary HIV infection does not affect virologic response to subsequent long-term treatment. PLoS One. 2014;9:e89639.
44. INSIGHT START Study Group. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373:795-807.
45. TEMPRANO ANRS 12136 Study Group. A trial of early antiretrovirals and isoniazid preventive therapy in Africa. N Engl J Med. 2015;373:808-822.
46. Le T, Wright EJ, Smith DM, et al. Enhanced CD4+ T-cell recovery with earlier HIV-1 antiretroviral therapy. N Engl J Med. 2013;368:218-30.
47. Bottani GM, Oreni ML, Orofino G, et al. Treatment outcome in HIV+ patients receiving 3- or 4-drug regimens during PHI. J Int AIDS Soc. 2014;17:19778.
48. Hunt PW, Martin JN, Sinclair E, et al. T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis. 2003;187:1534-43.
49. Jain V, Hartogensis W, Bacchetti P, et al. Antiretroviral therapy initiated within 6 months of HIV infection is associated with lower T-cell activation and smaller HIV reservoir size. J Infect Dis. 2013;208:1202-11.
50. Vinikoor MJ, Cope A, Gay CL, et al. Antiretroviral therapy initiated during acute HIV infection fails to prevent persistent T-cell activation. J Acquir Immune Defic Syndr. 2013;62:505-8.
51. Paci P, Martini F, Bernaschi M, D'Offizi G, Castiglione F. Timely HAART initiation may pave the way for a better viral control. BMC Infect Dis. 2011;11:56.
52. Oxenius A, Price DA, Easterbrook PJ, et al. Early highly active antiretroviral therapy for acute HIV-1 infection preserves immune function of CD8+ and CD4+ T lymphocytes. Proc Natl Acad Sci USA. 2000;97: 3382-7.
53. Rosenberg ES, Altfeld M, Poon SH, et al. Immune control of HIV-1 after early treatment of acute infection. Nature. 2000;407:523-6.
54. Altfeld M, Rosenberg ES, Shankarappa R, et al. Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection. J Exp Med. 2001;193:169-80.
55. Volberding P, Demeter L, Bosch RJ, et al. Antiretroviral therapy in acute and recent HIV infection: a prospective multicenter stratified trial of intentionally interrupted treatment. AIDS. 2009;23:1987-95.
56. Connick E, Bosch RJ, Aga E, Schlichtemeier R, Demeter LM, Volberding P. Augmented HIV-specific interferon-gamma responses, but impaired lymphoproliferation during interruption of antiretroviral treatment initiated in primary HIV infection. J Acquir Immune Defic Syndr. 2011;58:1-8.
57. Strain MC, Little SJ, Daar ES, et al. Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1. J Infect Dis. 2005;191:1410-8.
58. Chun TW, Justement JS, Moir S, et al. Decay of the HIV reservoir in patients receiving antiretroviral therapy for extended periods: implications for eradication of virus. J Infect Dis. 2007;195:1762-4.
59. Gianella S, von Wyl V, Fischer M, et al. Effect of early antiretroviral therapy during primary HIV-1 infection on cell-associated HIV-1 DNA and plasma HIV-1 RNA. Antivir Ther. 2011;16:535-45.
60. Lodi S, Meyer L, Kelleher AD, et al. Immunovirologic control 24 months after interruption of antiretroviral therapy initiated close to HIV seroconversion. Arch Intern Med. 2012;172:1252-5.
61. Hocqueloux L, Prazuck T, Avettand-Fenoel V, et al. Long-term immunovirologic control following antiretroviral therapy interruption in patients treated at the time of primary HIV-1 infection. AIDS. 2010;24:1598-601.
62. Saez-Cirion A, Bacchus C, Hocqueloux L, et al. Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog. 2013;9:e1003211.
63. Buzon MJ, Martin-Gayo E, Pereyra F, et al. Long-term antiretroviral treatment initiated at primary HIV-1 infection affects the size, composition, and decay kinetics of the reservoir of HIV-1-infected CD4 T cells. J Virol. 2014;88:10056-65.
64. Archin NM, Vaidya NK, Kuruc JD, et al. Immediate antiviral therapy appears to restrict resting CD4+ cell HIV-1 infection without accelerating the decay of latent infection. Proc Natl Acad Sci USA. 2012;109:9523-8.
65. Macal M, Sankaran S, Chun TW, et al. Effective CD4+ T-cell restoration in gut-associated lymphoid tissue of HIV-infected patients is associated with enhanced Th17 cells and polyfunctional HIV-specific T-cell responses. Mucosal Immunol. 2008;1:475-88.
66. Read SW, Ciccone EJ, Mannon PJ, et al. The effect of intermittent IL-2 therapy on CD4 T cells in the gut in HIV-1-infected patients. J Acquir Immune Defic Syndr. 2011;56:340-3.
67. Verhoeven D, Sankaran S, Silvey M, Dandekar S. Antiviral therapy during primary simian immunodeficiency virus infection fails to prevent acute loss of CD4+ T cells in gut mucosa but enhances their rapid restoration through central memory T cells. J Virol. 2008;82:4016-27.
68. Mehandru S, Poles MA, Tenner-Racz K, et al. Lack of mucosal immune reconstitution during prolonged treatment of acute and early HIV-1 infection. PLoS Med. 2006;3:e484.
69. Cao W, Mehraj V, Trottier B, et al. Early initiation rather than prolonged duration of antiretroviral therapy in HIV infection contributes to the normalization of CD8+ T-cell counts. Clin Infect Dis. 2015. [In press].
70. Kok A, Hocqueloux L, Hocini H, et al. Early initiation of combined antiretroviral therapy preserves immune function in the gut of HIV-infected patients. Mucosal Immunol. 2015;8:127-40.
71. Puertas MC, Massanella M, Llibre JM, et al. Intensification of a raltegravir- based regimen with maraviroc in early HIV-1 infection. AIDS. 2014;28:325-34.
72. Chéret A, Nembot G, Mélard A, et al. Paradoxical impact of maraviroc/raltegravir added to HAART in acute HIV infection: ANRS 147 trial. 21st CROI 2014; Boston. [Abstract 549LB].
73. Markowitz M, Evering TH, Garmon D, et al. A randomized open-label study of 3- versus 5-drug combination antiretroviral therapy in newly HIV-1-infected individuals. J Acquir Immune Defic Syndr. 2014;66:140-7.
74. Adolescents PoAGfAa. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf.
75. Routy JP, Cao W, Mehraj V. Overcoming the challenge of diagnosis of early HIV infection: A stepping-stone to optimal patient management. Expert Rev Anti Infect Ther. 2015. [In press].